Target intelligence / Profile preview

Uridine diphosphate-glucuronosyltransferase (UGT) (UGT)

Target
UGT
Molecular classification
Enzyme, Transferase, Phase II metabolic enzyme, Glycosyltransferase
01

Overview

Uridine diphosphate-glucuronosyltransferases (UGTs) are a superfamily of membrane-bound enzymes primarily located in the endoplasmic reticulum of the liver, but also present in the kidneys, gastrointestinal tract, and other tissues (Meech et al., 2019). They play a critical role in Phase II metabolism by catalyzing the glucuronidation process, which involves the transfer of glucuronic acid from UDP-glucuronic acid to various endogenous and exogenous lipophilic compounds (Rowland et al., 2013). This conjugation increases the water solubility of substrates, such as bilirubin, steroid hormones, and numerous drugs, facilitating their elimination via bile or urine (Guillemette, 2003). Genetic variations in UGT genes, particularly UGT1A1, are clinically significant as they can lead to impaired metabolism of drugs like irinotecan, resulting in severe toxicity (StatPearls, 2023). Furthermore, UGTs are involved in the detoxification of environmental carcinogens, and their activity is a major determinant of drug pharmacokinetics and potential drug-drug interactions (PubMed, 2021). Understanding the specific isoforms, such as UGT1A1 and UGT2B7, is essential for predicting drug safety and efficacy in clinical settings (UniProt, 2023).

Other names
UDP-glucuronosyltransferaseGlucuronosyltransferaseUDPGTUDP-GTGlucuronyltransferase
02

Mechanism of action

UGTs catalyze the transfer of the glucuronic acid moiety from uridine diphosphate glucuronic acid (UDPGA) to nucleophilic functional groups of various lipophilic substrates, converting them into water-soluble glucuronides for biliary or renal excretion (Meech et al., 2019; Rowland et al., 2013).

03

Biological functions

Xenobiotic metabolismGlucuronidationBilirubin detoxificationSteroid hormone metabolismBile acid metabolism
04

Disease associations

Gilbert syndromeCrigler-Najjar syndromeHyperbilirubinemiaDrug-induced liver injuryCancer susceptibility
05

Safety considerations

Severe neutropenia and diarrhea (e.g., with irinotecan in UGT1A1 deficient patients) (StatPearls, 2023)Drug-drug interactions via enzyme inhibition or induction (Guillemette, 2003)Hyperbilirubinemia and associated conditions like Gilbert syndrome (UniProt, 2023)
06

Interacting drugs

Irinotecan

9 more in the full profile.

07

Biomarkers

UGT1A1*28 polymorphismUGT1A1*6 polymorphismSerum total bilirubin levelsUGT2B7*2 variant

Beyond the preview

Go deeper on Uridine diphosphate-glucuronosyltransferase (UGT) (UGT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Uridine diphosphate-glucuronosyltransferase (UGT) (UGT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call